Hereditary Systemic Amyloidosis Due to Asp76Asn Variant β<sub>2</sub>-Microglobulin
Sophie Valleix(Délégation Paris 5), Vittorio Bellotti(University of Pavia), Guy Touchard(Centre Hospitalier Universitaire de Poitiers), Philip N. Hawkins(The Royal Free Hospital), Stéfano Ricagno(University of Milan), Riccardo Porcari(University of Pavia), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Monica Stoppini(University of Pavia), Martino Bolognesi(University of Milan), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Pierre Lozeron(Université Paris-Sud), Mathieu Boimard(Université Paris Cité), P. Patrizia Mangione(University of Pavia), Sofia Giorgetti(University of Pavia), Mark B. Pepys(University College London), Thierry Maisonobe(Sorbonne Université), Jason D. Theis(Mayo Clinic), Brigitte Nédelec(Institut Cochin), Frank Bridoux(Université de Poitiers), David Adams(Mount Sinai Health System), Jean‐Michel Goujon(Centre Hospitalier Universitaire de Poitiers), Corinne Lacombe(Université de Poitiers), Julie A. Vrana(University of Gothenburg), Marc Delpech(Université Paris Cité), Catherine Lacroix(Bicêtre Hospital), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center)
Cited by 188
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k